Latest Breaking News On - Bcr nonmetastatic hormone sensitive prostate cancer - Page 1 : comparemela.com

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

Comunidad autonoma de catalunaAntonio alcarazAhsan arozullahOncology development at astellasUniversity hospital clinic of barcelonaDepartment of urologyEuropean commissionUniversity hospital clinicMedicinal productsHuman useEuropean medicines agencyOncology developmentBcr nonmetastatic hormone sensitive prostate cancer